Literature DB >> 15119550

Visceral leishmaniasis complicating a connective tissue disease: three case reports from Italy.

G Castellino1, M Govoni, A Lo Monaco, C Montecucco, F Colombo, F Trotta.   

Abstract

We report the occurrence of visceral leishmaniasis in three patients coming from the northern part of Italy treated with immunosuppressive drugs for different rheumatic conditions. This paper highlights the importance of adequate work-up in those patients presenting with serious clinical manifestations that can complicate, exacerbate or mimic a systemic connective tissue disorder. A prompt diagnosis is very important because visceral leishmaniasis has a high mortality and, if untreated, can be fatal.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15119550     DOI: 10.1191/0961203304lu518oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  4 in total

1.  Imported case of visceral leishmaniasis presenting as pancytopenia in a Norwegian patient treated with methotrexate and etanercept for psoriasis arthritis.

Authors:  Emilio Besada; Rune Johan Njålla; Johannes C Nossent
Journal:  Rheumatol Int       Date:  2012-08-12       Impact factor: 2.631

2.  Leishmania infantum leishmaniasis in corticosteroid--treated patients.

Authors:  Silvia Pittalis; Emanuele Nicastri; Francesco Spinazzola; Piero Ghirga; Michele De Marco; Maria Grazia Paglia; Pasquale Narciso
Journal:  BMC Infect Dis       Date:  2006-12-18       Impact factor: 3.090

3.  Effect of immunosuppressants on the parasite load developed in, and immune response to, visceral leishmaniasis: A comparative study in a mouse model.

Authors:  Lorena Bernardo; Jose Carlos Solana; Alba Romero-Kauss; Carmen Sánchez; Eugenia Carrillo; Javier Moreno
Journal:  PLoS Negl Trop Dis       Date:  2021-02-01

4.  Prolonged fever, hepatosplenomegaly, and pancytopenia in a 46-year-old woman.

Authors:  Liran Levy; Abedelmajeed Nasereddin; Moshe Rav-Acha; Meirav Kedmi; Deborah Rund; Moshe E Gatt
Journal:  PLoS Med       Date:  2009-04-14       Impact factor: 11.069

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.